Enovis Corporation (ENOV) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $21.58, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment... Read more
Hold if already holding. Not a fresh buy at $21.58, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-17Recent Developments — Enovis Corporation
Latest news
- NEWS Despite fast-paced momentum, Enovis (ENOV) is still a bargain stock - MSN — MSN positive
- NEWS Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock - Yahoo Finance — Yahoo Finance positive
- NEWS Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says U - GuruFocus — GuruFocus neutral
- NEWS Enovis Corporation (ENOV) Stock: Is It Overpriced | Q4 2025: Profit Exceeds Views - Trending Entry Points - Newser — Newser positive
- NEWS William Blair Assigns Outperform Rating to Enovis (ENOV) - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-17T09:31:49Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $21.58, but acceptable to hold if already in. Reasons: Negative momentum; Elevated risk factors. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $37.41 (+73.4%), stop $20.07 (−7.5%), A.R:R 6.4:1. Score 5.7/10, moderate confidence.
Take-profit target: $37.41 (+73.4% upside). Target $37.41 (+73.4%), stop $20.07 (−7.5%), A.R:R 6.4:1. Stop-loss: $20.07.
Negative momentum; Elevated risk factors; Below 200-MA, MA slope -2.5%/30d (confirmed downtrend).
Enovis Corporation trades at a P/E of N/A (forward 5.2). TrendMatrix value score: 9.3/10. Verdict: Hold.
18 analysts cover ENOV with a consensus score of 4.2/5. Average price target: $43.
What does Enovis Corporation do?Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the...
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.